http://nanets.net/abstracts-archive/2021-1?format=html Fri, 05 Nov 2021 13:32:26 -0400 en-GB hourly 1 http://nanets.net/abstracts-archive/2021-1/1659-nanets-2021-abstracts-t6-etctn-10450-a-phase-1-trial-of-peposertib-and-lutetium-lu-177-dotatate-in-well-differentiated-somatostatin-receptor?format=html [T6] Chauhan - ETCTN 10450: a Phase 1 Trial of Peposertib and Lutetium Lu 177 Dotatate in Well-differentiated Somatostatin Receptor http://nanets.net/abstracts-archive/2021-1/1659-nanets-2021-abstracts-t6-etctn-10450-a-phase-1-trial-of-peposertib-and-lutetium-lu-177-dotatate-in-well-differentiated-somatostatin-receptor?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:32:26 -0400 http://nanets.net/abstracts-archive/2021-1/1658-nanets-2021-abstracts-t5-etctn-10388-a-phase-1-trial-of-triapine-and-lutetium-177-dotatate-in-well-differentiated-somatostatin-receptorpositive-gastroenteropancreatic-neuroendocrine-tumors?format=html [T5] Chauhan - ETCTN 10388: a Phase 1 Trial of Triapine and Lutetium 177 Dotatate in Well-differentiated Somatostatin Receptorpositive Gastroenteropancreatic Neuroendocrine Tumors http://nanets.net/abstracts-archive/2021-1/1658-nanets-2021-abstracts-t5-etctn-10388-a-phase-1-trial-of-triapine-and-lutetium-177-dotatate-in-well-differentiated-somatostatin-receptorpositive-gastroenteropancreatic-neuroendocrine-tumors?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:29:56 -0400 http://nanets.net/abstracts-archive/2021-1/1657-nanets-2021-abstracts-t4-a-phase-ii-trial-to-evaluate-the-safety-and-dosimetry-of-177lu-lu-dota-tate-in-adolescent-patients-with-somatostatin-receptor-sstr-positive-gastroenteropancreatic-neuroendocrine-tumors-gep?format=html [T4] O'Dorisio - A Phase II Trial to Evaluate the Safety and Dosimetry of [177Lu]Lu-DOTA-TATE in Adolescent Patients with Somatostatin Receptor (SSTR)-positive Gastroenteropancreatic Neuroendocrine Tumors (GEP http://nanets.net/abstracts-archive/2021-1/1657-nanets-2021-abstracts-t4-a-phase-ii-trial-to-evaluate-the-safety-and-dosimetry-of-177lu-lu-dota-tate-in-adolescent-patients-with-somatostatin-receptor-sstr-positive-gastroenteropancreatic-neuroendocrine-tumors-gep?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:21:42 -0400 http://nanets.net/abstracts-archive/2021-1/1656-nanets-2021-abstracts-t3-177lu-lu-dota-tate-as-first-line-therapy-for-patients-with-grade-2-and-3-advanced-gastroenteropancreatic-neuroendocrine-tumors-gep-nets-the-netter-2-study?format=html [T3] Singh - [177Lu]Lu-DOTA-TATE as First-line Therapy for Patients with Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): the NETTER-2 Study http://nanets.net/abstracts-archive/2021-1/1656-nanets-2021-abstracts-t3-177lu-lu-dota-tate-as-first-line-therapy-for-patients-with-grade-2-and-3-advanced-gastroenteropancreatic-neuroendocrine-tumors-gep-nets-the-netter-2-study?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:20:03 -0400 http://nanets.net/abstracts-archive/2021-1/1655-nanets-2021-abstracts-t2-dose-selection-for-paltusotine-a-once-daily-oral-nonpeptide-somatostatin-receptor-2-ligand-for-the-treatment-of-patients-with-carcinoid-syndrome-cs?format=html [T2] Lagast - Dose Selection for Paltusotine, a Once Daily Oral Nonpeptide, Somatostatin Receptor 2 Ligand, for the Treatment of Patients with Carcinoid Syndrome (CS) http://nanets.net/abstracts-archive/2021-1/1655-nanets-2021-abstracts-t2-dose-selection-for-paltusotine-a-once-daily-oral-nonpeptide-somatostatin-receptor-2-ligand-for-the-treatment-of-patients-with-carcinoid-syndrome-cs?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:19:24 -0400 http://nanets.net/abstracts-archive/2021-1/1654-nanets-2021-abstracts-t1-safety-pharmacodynamic-and-antitumor-activity-of-tidutamab-an-sstr2-x-cd3-bispecific-antibody-in-subjects-with-advanced-neuroendocrine-tumors?format=html [T1] El-Rayes - Safety, Pharmacodynamic, and Antitumor Activity of Tidutamab, an SSTR2 x CD3 Bispecific Antibody, in Subjects with Advanced Neuroendocrine Tumors http://nanets.net/abstracts-archive/2021-1/1654-nanets-2021-abstracts-t1-safety-pharmacodynamic-and-antitumor-activity-of-tidutamab-an-sstr2-x-cd3-bispecific-antibody-in-subjects-with-advanced-neuroendocrine-tumors?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:18:37 -0400 http://nanets.net/abstracts-archive/2021-1/1653-nanets-2021-abstracts-p12-mdt-experience-in-argentina-in-nets-in-times-of-the-covid19-pandemic?format=html [P12] Albor - MDT Experience in Argentina in Nets in Times of the Covid19 Pandemic http://nanets.net/abstracts-archive/2021-1/1653-nanets-2021-abstracts-p12-mdt-experience-in-argentina-in-nets-in-times-of-the-covid19-pandemic?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:17:30 -0400 http://nanets.net/abstracts-archive/2021-1/1652-nanets-2021-abstracts-p11-the-epidemiology-of-mixed-acinar-neuroendocrine-carcinoma-of-the-pancreas-in-the-united-states?format=html [P11] Abdelrahman - The Epidemiology of Mixed Acinar Neuroendocrine Carcinoma of the Pancreas in the United States http://nanets.net/abstracts-archive/2021-1/1652-nanets-2021-abstracts-p11-the-epidemiology-of-mixed-acinar-neuroendocrine-carcinoma-of-the-pancreas-in-the-united-states?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:16:52 -0400 http://nanets.net/abstracts-archive/2021-1/1651-nanets-2021-abstracts-p10-covid-19-in-patients-with-neuroendocrine-tumors-nets-the-mayo-clinic-experience?format=html [P10] Rakshit - Covid-19 in Patients with Neuroendocrine Tumors (NETs): the Mayo Clinic Experience http://nanets.net/abstracts-archive/2021-1/1651-nanets-2021-abstracts-p10-covid-19-in-patients-with-neuroendocrine-tumors-nets-the-mayo-clinic-experience?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:16:10 -0400 http://nanets.net/abstracts-archive/2021-1/1650-nanets-2021-abstracts-p9-the-impact-of-sociodemographic-factors-on-overall-survival-for-patients-with-adrenocortical-carcinomas-in-california?format=html [P9] Mulvey - The Impact of Sociodemographic Factors on Overall Survival for Patients with Adrenocortical Carcinomas in California http://nanets.net/abstracts-archive/2021-1/1650-nanets-2021-abstracts-p9-the-impact-of-sociodemographic-factors-on-overall-survival-for-patients-with-adrenocortical-carcinomas-in-california?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:15:04 -0400 http://nanets.net/abstracts-archive/2021-1/1649-nanets-2021-abstracts-p8-association-between-hospital-volume-and-overall-survival-of-pancreatic-neuroendocrine-tumors?format=html [P8] Harsha Tella - Association Between Hospital Volume and Overall Survival of Pancreatic Neuroendocrine Tumors http://nanets.net/abstracts-archive/2021-1/1649-nanets-2021-abstracts-p8-association-between-hospital-volume-and-overall-survival-of-pancreatic-neuroendocrine-tumors?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:14:18 -0400 http://nanets.net/abstracts-archive/2021-1/1648-nanets-2021-abstracts-p7-prevalence-and-presentation-of-cushing-and-carcinoid-syndromes-in-patients-with-non-metastatic-primary-lung?format=html [P7] Lee - Prevalence and Presentation of Cushing and Carcinoid Syndromes in Patients with Non-metastatic Primary Lung http://nanets.net/abstracts-archive/2021-1/1648-nanets-2021-abstracts-p7-prevalence-and-presentation-of-cushing-and-carcinoid-syndromes-in-patients-with-non-metastatic-primary-lung?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:13:41 -0400 http://nanets.net/abstracts-archive/2021-1/1647-nanets-2021-abstracts-p6-surgical-interventions-in-patients-with-pancreatic-neuroendocrine-tumors-a-seer-based-survival-analysis?format=html [P6] Zarate Rodriguez - Surgical Interventions in Patients with Pancreatic Neuroendocrine Tumors: a SEER-based Survival Analysis http://nanets.net/abstracts-archive/2021-1/1647-nanets-2021-abstracts-p6-surgical-interventions-in-patients-with-pancreatic-neuroendocrine-tumors-a-seer-based-survival-analysis?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:13:05 -0400 http://nanets.net/abstracts-archive/2021-1/1646-nanets-2021-abstracts-p5-race-is-an-independent-predictor-for-surgery-offer-in-patients-with-small-bowel-neuroendocrine-tumors-but-not-pancreatic-neuroendocrine-tumors?format=html [P5] Zarate Rodriguez - Race is an Independent Predictor for Surgery Offer in Patients with Small Bowel Neuroendocrine Tumors But Not Pancreatic Neuroendocrine Tumors http://nanets.net/abstracts-archive/2021-1/1646-nanets-2021-abstracts-p5-race-is-an-independent-predictor-for-surgery-offer-in-patients-with-small-bowel-neuroendocrine-tumors-but-not-pancreatic-neuroendocrine-tumors?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:12:21 -0400 http://nanets.net/abstracts-archive/2021-1/1645-nanets-2021-abstracts-p4-secondary-primary-cancers-and-survival-among-neuroendocrine-tumor-patients?format=html [P4] Bateni - Secondary Primary Cancers and Survival among Neuroendocrine Tumor Patients http://nanets.net/abstracts-archive/2021-1/1645-nanets-2021-abstracts-p4-secondary-primary-cancers-and-survival-among-neuroendocrine-tumor-patients?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:11:47 -0400 http://nanets.net/abstracts-archive/2021-1/1644-nanets-2021-abstracts-p3-incidence-and-predictors-of-second-cancers-in-neuroendocrine-tumors?format=html [P3] Bateni - Incidence and Predictors of Second Cancers in Neuroendocrine Tumors http://nanets.net/abstracts-archive/2021-1/1644-nanets-2021-abstracts-p3-incidence-and-predictors-of-second-cancers-in-neuroendocrine-tumors?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:10:59 -0400 http://nanets.net/abstracts-archive/2021-1/1643-nanets-2021-abstracts-p2-incidence-of-psychiatric-illness-in-patients-with-neuroendocrine-tumors-a-comparative-population-based?format=html [P2] Hallet - Incidence of Psychiatric Illness in Patients With Neuroendocrine Tumors - A Comparative Population-Based http://nanets.net/abstracts-archive/2021-1/1643-nanets-2021-abstracts-p2-incidence-of-psychiatric-illness-in-patients-with-neuroendocrine-tumors-a-comparative-population-based?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:10:17 -0400 http://nanets.net/abstracts-archive/2021-1/1642-nanets-2021-abstracts-p1-predictors-and-outcomes-of-minimally-invasive-surgery-for-small-bowel-neuroendocrine-tumors?format=html [P1] Wong - Predictors And Outcomes Of Minimally Invasive Surgery For Small Bowel Neuroendocrine Tumors http://nanets.net/abstracts-archive/2021-1/1642-nanets-2021-abstracts-p1-predictors-and-outcomes-of-minimally-invasive-surgery-for-small-bowel-neuroendocrine-tumors?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:09:38 -0400 http://nanets.net/abstracts-archive/2021-1/1641-nanets-2021-abstracts-o8-understanding-neuroendocrine-tumour-patient-preferences-for-medical-management-of-midgut-nets-using-discrete-choice-experiments-a-direct-nets-study?format=html [O8] Anaka - Understanding Neuroendocrine Tumour Patient Preferences for Medical Management of Midgut NETs Using Discrete Choice Experiments: a DIRECT NETs Study http://nanets.net/abstracts-archive/2021-1/1641-nanets-2021-abstracts-o8-understanding-neuroendocrine-tumour-patient-preferences-for-medical-management-of-midgut-nets-using-discrete-choice-experiments-a-direct-nets-study?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:08:44 -0400 http://nanets.net/abstracts-archive/2021-1/1640-nanets-2021-abstracts-o7-succinate-dehydrogenase-pathogenic-variants-are-not-associated-with-non-canonical-cancers?format=html [O7] Wachtel - Succinate Dehydrogenase Pathogenic Variants are Not Associated with Non-canonical Cancers http://nanets.net/abstracts-archive/2021-1/1640-nanets-2021-abstracts-o7-succinate-dehydrogenase-pathogenic-variants-are-not-associated-with-non-canonical-cancers?format=html wertherm@adgcommunications.com (Maureen Werther) 2021 Fri, 05 Nov 2021 13:08:10 -0400